The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes

Title:The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes

Volume: 13 Issue: 3

Author(s): Piero Ruscitti*, Paola Cipriani, Vasiliky Liakouli, Francesco Carubbi, Onorina Berardicurti, Paola Di Benedetto, Francesco Ciccia, Giuliana Guggino, Saverio Alvaro, Giovanni Triolo and Roberto Giacomelli

Affiliation:

• Rheumatology Section, Department of Biotechnological and Applied Clinical Sciences, University of L`Aquila, L`Aquila,Italy

Keywords: Anakinra, cardiovascular risk, diabetes, IL-1β, pathogenesis, rheumatoid arthritis, therapy.

Abstract: Background: Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients.

Objective: We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process.

Method: After literature search, the available evidence has been selected and commented in the text.

Results: During RA, it is well known that different inflammatory cytokines, such as interleukin-1β (IL-1β), are pivotal pathogenic mediators and their role has been largely confirmed in clinical settings. Similarly, it has been shown that the excess of nutrients, secondary to over-nutrition, may activate the immune system, leading to an increased production of inflammatory cytokines, including IL-1β, suggesting new possible therapeutic targets.

Conclusion: Although further studies are needed to fully investigate the pathogenic interplay between inflammation and metabolic disorders, IL-1β has been implicated in both RA and T2D pathogenic mechanisms. Intriguingly, the potential role of anti-IL-1 drugs has been proposed in RA patients affected by T2D.

Cite this article as:

Ruscitti Piero*, Cipriani Paola, Liakouli Vasiliky, Carubbi Francesco, Berardicurti Onorina, Di Benedetto Paola, Ciccia Francesco, Guggino Giuliana, Alvaro Saverio, Triolo Giovanni and Giacomelli Roberto, The Emerging Role of IL-1 Inhibition in Patients Affected by Rheumatoid Arthritis and Diabetes, Reviews on Recent Clinical Trials 2018; 13 (3) . https://dx.doi.org/10.2174/1574887113666180314102651